| Authors |
Płudowski, Paweł ; Kos-Kudła, Beata ; Walczak, Mieczysław ; Fal, Andrzej ; Zozulińska-Ziółkiewicz, Dorota ; Sieroszewski, Piotr ; Peregud-Pogorzelski, Jarosław ; Lauterbach, Ryszard ; Targowski, Tomasz ; Lewiński, Andrzej ; Spaczyński, Robert ; Wielgoś, Mirosław ; Pinkas, Jarosław ; Jackowska, Teresa ; Helwich, Ewa ; Mazur, Artur ; Ruchała, Marek ; Zygmunt, Arkadiusz ; Szalecki, Mieczysław ; Bossowski, Artur ; Czech-Kowalska, Justyna ; Wójcik, Marek ; Pyrżak, Beata ; Żmijewski, Michał A ; Abramowicz, Paweł ; Konstantynowicz, Jerzy ; Marcinowska-Suchowierska, Ewa ; Bleizgys, Andrius ; Karras, Spirydon N ; Grant, William B ; Carlberg, Carsten ; Pilz, Stefan ; Holick, Michael F ; Misiorowski, Waldemar |
| Abstract [eng] |
Introduction: All epidemiological studies suggest that vitamin D deficiency is prevalent among the Polish general population. Since vitamin D deficiency was shown to be among the risk factors for many diseases and for all-cause mortality, concern about this problem led us to update the previous Polish recommendations. Methods: After reviewing the epidemiological evidence, case-control studies and randomized control trials (RCTs), a Polish multidisciplinary group formulated questions on the recommendations for prophylaxis and treatment of vitamin D deficiency both for the general population and for the risk groups of patients. The scientific evidence of pleiotropic effects of vitamin D as well as the results of panelists’ voting were reviewed and discussed. Thirty-four authors representing different areas of expertise prepared position statements. The consensus group, representing eight Polish/international medical societies and eight national specialist consultants, prepared the final Polish recommendations. Results: Based on networking discussions, the ranges of total serum 25-hydroxyvitamin D concentration indicating vitamin D deficiency [<20 ng/mL (<50 nmol/L)], suboptimal status [20–30 ng/mL (50–75 nmol/L)], and optimal concentration [30–50 ng/mL (75–125 nmol/L)] were confirmed. Practical guidelines for cholecalciferol (vitamin D3) as the first choice for prophylaxis and treatment of vitamin D deficiency were developed. Calcifediol dosing as the second choice for preventing and treating vitamin D deficiency was introduced. Conclusions: Improving the vitamin D status of the general population and treatment of risk groups of patients must be again announced as healthcare policy to reduce a risk of spectrum of diseases. This paper offers consensus statements on prophylaxis and treatment strategies for vitamin D deficiency in Poland. |
